Blog

  • Culturally relevant pain solutions

    Culturally relevant pain solutions

    After training as a musculoskeletal physiotherapist in India, the Kolling Institute’s Dr Saurab Sharma returned to Nepal to treat patients with musculoskeletal pain conditions but quickly found that Western practices to assess and treat pain didn’t translate well to his community. One issue was the internationally-recognised numeric pain rating scale, where zero indicates no pain and 10 is maximum pain.

    “Some people in Nepal struggle with it because they can’t compute numbers in their head,” he explains, making it difficult for them to rate their pain accurately. “Also, not many people take surveys in their day-to-day life. For many, it’s the first time in their life.”

    Saurab also noticed a lack of local research. “There’s no research on musculoskeletal pain in my region, specifically back pain,” he says. To address this, he collaborated with Professor Mark Jensen, a prominent pain researcher, and later completed a PhD in New Zealand.

    Now Chief Scientist for Clinical Research at the Kolling’s Pain Management and Research Centre Saurab emphasises the need for more pain research in low and middle-income countries, as well as culturally relevant interventions for diverse communities in Australia.

    Saurab’s work has focused largely on Nepal. He compared four pain scales and found that the numeric scale had the highest error rate and was disliked by patients.

    The “Faces rating scale,” which uses facial expressions to indicate pain intensity had the best results and was preferred by patients.

    He has translated and validated 29 pain assessment tools for Nepal, but there’s still more work to be done. He also developed educational resources using local language and metaphors to describe pain; they have now been adapted for four countries and languages.

    Importantly, he believes the West can learn from Nepal’s approaches to pain management. In countries with limited access to multidisciplinary teams, peer support groups in communities often play a vital role.

    “We could implement similar models here in Australia,” he suggests, proposing that individuals could be trained for a few days in evidence-based pain management and then support others in their community.

    To boost back pain research, Saurab formed a consortium of researchers, clinicians, and patients from 35 low- and middle-income countries. “In many countries, there’s no local pain research. We don’t even know how back pain is managed.”

    In a recent study, he found that in majority of countries patients have to rely on pharmacotherapy and electrotherapy, neither of which is recommended. Harmful interventions with no evidence of effectiveness such as bloodletting is also used in some countries.

    “Education and self-management are recommended by most global back pain guidelines but are rarely used,” Saurab notes. He’s now developing interventions to treat pain in Australia’s diverse communities, including Nepali, Chinese, Indian, and Vietnamese populations. 

  • Practical tool to offer better informed care for people living with dementia

    Practical tool to offer better informed care for people living with dementia

    Our researchers at the Kolling Institute are working to improve the use of medications for dementia with a comprehensive analysis highlighting several concerning trends.

    The latest data indicates more than 420,000 people are living with dementia in Australia, including more women than men. The condition is the second leading cause of death in Australia.

    Leading researcher and member of the Kolling’s Neuroscience and Pain Priority Research Area Dr Edwin Tan said people with dementia are high users of medications due to the challenging symptoms of the condition and the combination of other chronic conditions.

    “We found there was often limited evidence for prescribing medications for people with dementia, and clinicians were left to weigh up the risks and benefits of these medications,” he said.

    “Our analysis of nationwide data found 60 per cent of people with dementia are taking a psychotropic medication like an anti-depressant, antipsychotic or opioid, and 26 per cent are taking an anti-dementia medication like Aricept, Exelon or Reminyl.

    “We were interested to find that when we looked at people’s backgrounds, those from a higher socio-economic group were more likely to take an anti-dementia medication, compared with people from a rural or regional area, or those with limited access to healthcare, who were more likely to take a psychotropic drug, like an antipsychotic.

    “Concerningly, two thirds of people with dementia are taking at least five medications and 23 per cent are taking more than ten medications.”

    Researchers were also concerned to see the number of high-risk combinations of drugs, with 14 per cent of people with dementia taking all four high-risk medication groups, including sedatives.

    The data pointed to an increased risk of medication poisoning, with one in five people experiencing an adverse drug event. Researchers identified 15 per cent of people with dementia experienced drug poisoning, compared with just two per cent of the general older population.

    Dementia increased a person’s risk of poisoning by an alarming 77 per cent.

    Dr Tan is now working to develop a personalised antipsychotic calculator to assist with safer prescribing and shared decision making.

    “Working with patients, clinicians and carers, I am keen to develop a tool which will weigh the risks and benefits of antipsychotic medications to help ensure patients are prescribed the best medication for their individual needs.

    “An evidenced-based tool, which would predict the likelihood of treatment response and adverse events, could greatly assist personal treatment plans and improve patient outcomes.”

  • Award raises profile of early career research at the Kolling Institute

    Award raises profile of early career research at the Kolling Institute

    Two of the Kolling Institute’s emerging leaders are gaining attention after receiving the ATA Scientific Encouragement Award.

    The award, which was launched more than a decade ago, aims to provide young scientists with financial assistance to further their education and attend scientific meetings and conferences.

    Scientific officer Kevin Winardi from the Kolling’s Lab of Ageing and Pharmacology will attend two bioinformatics conferences after receiving the award.

    His work focuses on understanding the molecular mechanisms behind drug-related harms in older people, and whether the adverse effects of medications can be reversed once the medications are stopped.

    Kevin’s goal is to expand his research into pharmacology, ageing biology and systems biology to enhance the care of older people.

    Attending the conferences will provide Kevin with a valuable opportunity to explore a new bioinformatics tool and connect with leading national experts.

    His colleague from the Lab of Ageing and Pharmacology PhD student Temitope Esther Afolabi has also taken out an encouragement award, which will help her attend a medications management conference in South Australia in November.

    Esther will deliver a presentation at the event, detailing her work to improve the quality use of medications by older people through an online patient decision support tool.

    Esther believes the tool could be a safe, evidence-based and cost-effective innovation to promote optimal health.

    Kevin and Esther would like to thank ATA Scientific for the important opportunities provided through their encouragement awards.   

  • Research to improve postmenopausal women’s bone and muscle health

    Research to improve postmenopausal women’s bone and muscle health

    Kolling Institute researchers Dr. Shejil Kumar and Professor Rory Clifton-Bligh have embarked on a pioneering study to enhance bone health in postmenopausal women.

    The study, titled “Combining Osteoanabolic Pharmacotherapy with Osteogenic Exercise in Postmenopausal Women with Osteoporosis and Osteopenia “The ROLEX-DUO Study,” is set to recruit 100 women aged 50 and above.

    The primary focus of the study is to assess the effectiveness of combining exercise plus medication in improving bone and muscle health.

    “We know that exercise has benefits for bone and muscle health, and there are effective treatments available to strengthen bones,” Dr. Kumar said.

    “However, what we don’t know is whether combining exercise plus medication at the same time can lead to even greater improvements in bone and muscle health than treating with either alone.”

    The study will utilise a medication that has been shown to increase bone density and reduce fracture risk in previous international studies. Participants will be randomly assigned to different treatment groups, including a supervised group class focusing on weightbearing exercises and a home-based exercise program concentrating on mobility and balance.

    “We are investigating if this combination will be more effective and could change the way we treat and prevent osteoporosis going forward.”

    Postmenopausal women between the ages of 50 and 80 are encouraged to participate, as they are at high risk of poor bone health. The study aims to assess how different combinations of treatment improve bone density, muscle strength, body composition, physical function and risk of falls.

    The study will primarily be based at Royal North Shore Hospital.

    If you would like to be part of the study, you can register here:

    If you have any queries, you can email Dr. Kumar at shejil.kumar@health.nsw.gov.au  

    The study has obtained ethics approval from the NSLHD ethics committee (2022/ETH01794).

  • Crucial steps towards gene therapy for debilitating Meniere’s disease

    Crucial steps towards gene therapy for debilitating Meniere’s disease

    Our researchers at the Kolling Institute are at the forefront of Meniere’s disease science developing the first humanised model of the disease ahead of gene therapy.

    The specialised team is led by world-leading Meniere’s disease researcher and neuroscientist Professor Jose Antonio Lopez-Escamez who relocated from Spain to the institute to pursue his ground-breaking work.

    His talented team of seven is set to grow to a dozen by 2025.

    Professor Lopez-Escamez said it was an exciting time for research in this area as we move into precision medicine with specific drugs, and develop gene therapy for the next generation of patients with the disease which causes vertigo and hearing loss.

    “We are making encouraging progress as we investigate the genetic basis of the disease, finding that many patients have a recessive inheritance where both parents are carriers of the disease but don’t have any symptoms,” he said.

    “When I was working as an ENT surgeon in Spain more than 10 years ago, the condition was largely neglected and not well understood, and many patients were not doing well.

    “Today, we are learning more about the disease and the broad range of influences, including immune-response inflammation, allergy and migraine.”

    “We are now investigating the genetic mutations involved in the disease in preclinical models in a crucial step towards the development of gene therapy. We believe this game-changing approach will be available within the next 10 years.

    “Importantly, we must consider that people will have different genetic and immune backgrounds, and different associated conditions, like migraine.

    “It is not the same disease for all individuals and will present differently.

    “We don’t have a magic pill that is going to work for everybody with Meniere’s. For some patients some medication will work, one drug will be better. But for others there will be another way.

    “That’s why it’s important we know which subgroup of Meniere’s a patient has.”

    Global database

    Another important part of Antonio’s work is to establish a global website database with genomic information from patients’ blood tests that enable genetic diagnosis in the future.

    The database will help researchers, doctors and ultimately patients.

    “It will be like a reference portal to train researchers and a tool for doctors,” he said.

    “Genetic testing is a very important step to get more knowledge about the basis of many diseases.

    “My idea is that any doctor can upload a file on the website and compare individual patients’ data with the reference data that we have generated. It will be useful and accessible.”

  • Special Research Feature – Year in Review 2023

    Special Research Feature – Year in Review 2023

    Our Kolling Institute Year in Review profiles our innovative and life-changing research across the Kolling Institute.

    Our researchers are driving investigations into some of the most challenging health conditions from heart and kidney disease to musculoskeletal conditions, chronic pain, cancer and neurodegenerative disorders.

    Our teams have continued to increase their research impact, while forging significant new collaborations. They have maintained a commitment to research excellence, while securing large-scale funding, receiving high profile awards and publishing impactful studies.

    We hope this feature will give you a better insight into our impressive and unique teams, and their ground-breaking research. We would like to extend our thanks to our many wonderful donors who help us deliver real improvements to the care we all receive. Click here to read the feature:

  • World first research to develop cognitive impairment guidelines after spinal cord injury

    World first research to develop cognitive impairment guidelines after spinal cord injury

    A team of researchers from the Kolling Institute’s John Walsh Centre for Rehabilitation Research has launched a study to develop the first internationally accepted guidelines for assessing cognitive function after a spinal cord injury.

    The latest data indicates that over 15 million people globally live with a spinal cord injury, and in Australia, there are over 20,000 people living with the injury.

    There are around 300-400 new cases of this injury every year in Australia.

    The devastating physical impact of these injuries has been extensively studied from the loss of motor control (such as paralysis) to the pain and sensory issues, and the significant problems with cardiovascular and respiratory function.

    However, the psychological and cognitive impacts of this severe neurological injury have not been as well understood, such as the extent of cognitive impairment and mental health disorders over time.

    There is now a growing body of evidence around the psychosocial consequences of a spinal cord injury, with new studies by the John Walsh Centre for Rehabilitation Research highlighting a concerning trend.

    Professor of Rehabilitation Ashley Craig said we are just completing the first ever study conducted anywhere internationally that has assessed cognitive function and potential cognitive impairment in adults with a spinal cord injury from soon after their injury in the acute stage, until their discharge from rehabilitation up to 12 months post injury.

    “Our research found that at least 30 per cent of adults with a spinal cord injury were assessed as having at least mild cognitive impairment, and that this impairment was identified as a major risk factor for the development of mental health disorders like depressive mood and anxiety after the person is discharged from hospital,” he said.

    “This is very concerning given that this may result, not only in a higher risk of a mental health disorder in those with cognitive impairment, but also an increased risk of secondary health conditions like chronic pain, skin problems like pressure ulcers, and respiratory infections. The person with cognitive impairment may become confused and overwhelmed about how best to self-manage these conditions.

    “Despite the high number of people experiencing these challenges, our research has identified there are currently no internationally-recognised cognitive assessment tests suitable for measuring cognitive function after a spinal cord injury.”

    Our team has now begun research to develop a new framework for cognitive screening, which will involve sensitive and valid cognitive assessment tools.

    “This is an important body of work which will build on our prior research to validate the cognitive domain areas we have previously identified that affect most adults with spinal cord injury. We will then develop alternative ways of assessing day to day cognitive function in conjunction with established neurocognitive tests we currently use that are limited.”

    “We know that there are multiple possible causes of cognitive impairment after spinal cord injury, such as age, polypharmacy, level of lesion, mental health, fatigue, and autonomic function. Our framework must attempt to account for these possible affects”, Professor Craig said.

    The John Walsh team will work with international partners in the UK, Europe and the USA, who are keen to collaborate in the development of a new cognitive assessment framework.

    This research will be informed by another current study that is investigating how best to integrate guidelines for psychosocial health and cognitive care with the multidisciplinary health teams managing spinal cord patients in the units at Royal North Shore Hospital, Prince of Wales Hospital and Royal Rehab.

    The John Walsh team developed these guidelines which are available on the Agency for Clinical Innovation website: 

    The team involved is Prof Ashley Craig and Prof James Middleton, Dr Mohit Arora, Dr Ilaria Pozzato, Dr Candice McBain, Dr Danielle Sandalic, Daniel Myles, Anne Marie Sarandrea, Dr Jazbeer Kaur and Dr Yvonne Tran. 

  • Innovative musculoskeletal program heads to the bush

    Innovative musculoskeletal program heads to the bush

    In a sign of the strength of the Kolling Institute’s research and clinical capabilities, Professor Trudy Rebbeck has been awarded a $2.5 million grant to offer a musculoskeletal care program in rural and remote parts of Australia.

    As a Professor of Allied Health and a physiotherapist, Trudy will lead the collaborative project involving University of Sydney, NSLHD and Kolling Institute researchers Michael Nicholas, Ian Cameron, Annette Kifley and Claire Ashton-James.

    She is excited to launch the initiative which has been funded as part of a $20 million boost for improved primary care and chronic pain treatment.

    Trudy said an increasing number of people are experiencing chronic musculoskeletal conditions like back, neck pain and arthritis, but few people in rural and regional areas are being offered evidence-informed care involving good advice and an exercise plan.

    “We know that people in these communities have poorer access to appropriate care and ultimately poorer musculoskeletal health,” she said.

    “Our large-scale program, named PACE RURAL, will be offered across the country for the first time, providing a high quality and yet low-cost solution.”

    It will involve a simple online tool at the point of care to identify people who may recover well and those who may not. Those who are likely to recover well can be guided by the online resource (Mypainhub.com) which provides accurate advice and exercises to aid recovery.

    People needing extra care will receive early virtual access to an expert allied health clinician.

    The allied-health specialist will work with the local GP through an advanced assessment of risk factors and develop an individualised treatment plan.

    “For many people living in rural and remote parts of Australia, one of the biggest challenges is access to specialised healthcare, so we hope that through this program, we will broaden access to evidenced-based, effective care and importantly, improve long-term musculoskeletal health,” she said.

    “We know from our work in metropolitan regions that increasing support from allied-health clinicians delivers better health outcomes for higher risk individuals, so we expect this project will now provide a cost-effective solution in rural and remote Australia too.” 

  • Recognition for emerging research leader

    Recognition for emerging research leader

    We would like to congratulate our early career researcher Dr Nashwa Masnoon from the Kolling’s Ageing and Pharmacology Lab who has taken out the ATA Scientific Young Scientist Encouragement Award.

    Nashwa, who is a postdoctoral research pharmacist, clinched the $1500 prize for her assessment of the risks and benefits of using artificial intelligence in research.

    The award will enable her to attend a high profile conference co-ordinated by the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists, the Asia Pacific Federation of Pharmacologists and the Australasian Pharmaceutical Science Association.

    Nashwa was thrilled to win the award and has welcomed the chance to attend the large scale event in Melbourne.

    Further details about the ATA Scientific competition and the next awards can be found here.

  • Kolling Institute researchers instrumental in Australian first guidelines

    Kolling Institute researchers instrumental in Australian first guidelines

    It has taken three years and many hours of careful work, but two researchers from the John Walsh Centre for Rehabilitation Research have developed the first clinical practice guidelines for physiotherapists to inform the care of people with life-changing spinal cord injuries.

    Physiotherapy is a key part of rehabilitation for people with a spinal cord injury, but until now, there has been no nationally consistent advice based on the best available evidence.

    The guidelines were driven by Professor Lisa Harvey and Associate Professor Joanne Glinsky, who worked with a team of physiotherapists, researchers, and people with a spinal cord injury across Australia and New Zealand.

    Professor Harvey said the recommendations provide up-to-date information on the most effective physiotherapy management.

    “Importantly, they are based on a rigorous evaluation of the available evidence, taking into account the opinions of clinical experts and people with a spinal cord injury,” she said.

    “We started the process by identifying over 100 clinical questions of importance to physiotherapists and those living with an injury, and each question was ultimately answered by way of an evidenced-based recommendation or a consensus statement.”

    Associate Professor Glinsky said we followed a very detailed and rigorous process with many meetings, discussions and reviews of the evidence.

    “It is this process that should give people confidence in the recommendations of the guidelines,” she said.

    Professor Harvey added that the work was only possible with the initial financial support from icare in NSW, and the support from organisations throughout Australia including the Transport Accident Commission, the National Insurance Scheme Queensland and the Lifetime Support Authority.

    “Their support for this important piece of work was critical to our success. We are tremendously grateful they shared our vision to create these first Australian recommendations.”

    The guidelines can be viewed at www.SCIPTguide.org 

NSWGOV logo